IRIDEXIRIX
IRIX
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
0.61% less ownership
Funds ownership: 20.01% [Q3] → 19.4% (-0.61%) [Q4]
4% less funds holding
Funds holding: 28 [Q3] → 27 (-1) [Q4]
7% less capital invested
Capital invested by funds: $5.83M [Q3] → $5.43M (-$394K) [Q4]
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
64% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 11
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $7K
Research analyst outlook
We haven’t received any recent analyst ratings for IRIX.
Financial journalist opinion
Based on 5 articles about IRIX published over the past 30 days
Neutral
Seeking Alpha
4 hours ago
IRIDEX Corporation (IRIX) Q4 2024 Earnings Call Transcript
IRIDEX Corporation (NASDAQ:IRIX ) Q4 2024 Earnings Conference Call March 27, 2025 5:00 PM ET Company Participants Trip Taylor - Investor Relations Department Patrick Mercer - Chief Executive Officer Romeo Dizon - Chief Financial Officer Conference Call Participants Operator Hello. And welcome to the Fourth Quarter 2024 IRIDEX Earnings Conference Call.
Neutral
GlobeNewsWire
6 hours ago
Iridex Reports Fourth Quarter and Full Year 2024 Financial Results
MOUNTAIN VIEW, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended December 28, 2024.
Neutral
GlobeNewsWire
1 week ago
Iridex Announces Strategic Investment in the Company
MOUNTAIN VIEW, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the closing of a strategic investment in the company resulting in $10 million of gross proceeds along with an option by the investor to fund up to $10 million of additional proceeds for future growth initiatives (the “Transaction”). The sole counterparty to the Transaction is Novel Inspiration International Co., Ltd. (“Novel”), an investment company founded in 2020, which had the assistance of William Moore, formerly both a board member and Chief Executive Officer of the company.
Neutral
GlobeNewsWire
1 week ago
Iridex Comments on Recent Stock Price Volatility
MOUNTAIN VIEW, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today commented on its recent stock price volatility.
Neutral
GlobeNewsWire
2 weeks ago
Iridex to Report Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025
MOUNTAIN VIEW, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the fourth quarter and full year 2024 and provide a business update after the close of trading on Thursday, March 27, 2025.
Neutral
GlobeNewsWire
3 months ago
Iridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management
MOUNTAIN VIEW, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the publication of a landmark peer-reviewed study in Ophthalmology Therapy. This study highlights the sustained safety and efficacy of MicroPulse Transscleral Laser Therapy (TLT) (also referred to as Transscleral Cyclophotocoagulation) in managing both primary and secondary glaucoma over five years. Conducted by Dr. Ronald de Crom and colleagues at the University Eye Clinic Maastricht, Netherlands, this research is the first to evaluate outcomes of MicroPulse TLT over such an extended period.
Neutral
GlobeNewsWire
4 months ago
Iridex Comments on Changing Glaucoma Reimbursement Landscape
MOUNTAIN VIEW, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today confirms that Local Coverage Determination (LCD) L37531, relating to Micro-Invasive Glaucoma Surgery (MIGS), was adopted as scheduled and will be effective for services performed on or after November 17, 2024. The Company has previously reported that it believes the reimbursement limitations created by the new LCD has potential to significantly increase physician interest in and use of Iridex's advanced laser-based treatments for glaucoma.
Neutral
Seeking Alpha
4 months ago
IRIDEX Corporation (IRIX) Q3 2024 Earnings Call Transcript
IRIDEX Corporation (NASDAQ:IRIX ) Q3 2024 Earnings Call Transcript November 12, 2024 5:00 PM ET Company Participants Scott Shuda - Executive Chairman Patrick Mercer - CEO Fuad Ahmad - Interim CFO Operator Thank you all for participating in today's call. Joining me from the company are Scott Shuda, Executive Chairman; Patrick Mercer, Chief Executive Officer; and Fuad Ahmad, Interim Chief Financial Officer.
Neutral
GlobeNewsWire
4 months ago
Iridex to Report Third Quarter 2024 Financial Results on November 12, 2024
MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter 2024 and provide a business update after the close of trading on Tuesday, November 12, 2024.
Neutral
GlobeNewsWire
5 months ago
Iridex Appoints Patrick Mercer as Chief Executive Officer
MOUNTAIN VIEW, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the appointment of Patrick Mercer as the Company's Chief Executive Officer and President effective October 1, 2024. Previously Mr. Mercer served as the Company's Chief Operating Officer and President. David Bruce, the Company's prior Chief Executive Officer, is transitioning from the Company. Coincident to Mr. Mercer's appointment, Scott Shuda was appointed Executive Chairman of the Company's board of directors. Mr. Shuda had previously served as Chairman.
Charts implemented using Lightweight Charts™